Reported 11 months ago
Cathie Wood, the founder of Ark Invest, is known for investing in innovative companies at great prices. Recently, she has added to her positions in CRISPR Therapeutics and Intellia Therapeutics, two companies specializing in gene editing technologies. CRISPR Therapeutics recently launched its first product for blood disorders and has a strong cash position, while Intellia Therapeutics is progressing towards late-stage clinical trials for potential treatments. Despite stock price declines, Wood sees these investments as opportunities for future growth.
Source: YAHOO